On a day where the S&P/ASX 200 Index (ASX: XJO) is up 0.25%, there are a few ASX 200 shares that are performing strongly.
With the period ending December 2022 now finished, businesses are giving some updates.
While some companies use this pre-February time to tell the market they're underperforming against expectations, investors have been impressed by the following ASX 200 shares.
Pilbara Minerals Ltd (ASX: PLS)
The Pilbara Minerals share price is currently up 9.8% after announcing its quarterly update for the three months to December 2022.
The ASX 200 lithium miner revealed its production had increased by 10% quarter over quarter to 162,151 dry metric tonnes (dmt).
The average realised spodumene concentrate sales price was US$5,688 per dmt, an increase of 33% quarter over quarter.
It also revealed its cash balance had increased by $851 million to $2.23 billion.
The company also reminded investors that it has seen improved pricing outcomes after negotiated price reviews with major offtake customers.
Whitehaven Coal Ltd (ASX: WHC)
As one of the major ASX 200 coal shares, Whitehaven is continuing to benefit from strong coal prices. The Whitehaven share price is up 7.3% after announcing its quarterly numbers today.
The company advised that in the three months to December 2022, a solid Narrabri performance and strong sales delivered a record half-year result, despite weather affecting open-cut operations.
Whitehaven achieved an average coal price of A$527 per tonne for the quarter, compared to A$581 for the three months to September 2022. In the three months to December 2022, it managed run-of-mine production of 4.8 mt, up 21% compared to the three months to 30 September 2022.
Subject to the final audit, Whitehaven expects to report that it made $2.6 billion of earnings before interest, tax, depreciation and amortisation (EBITDA) and $2.5 billion of operating cash flow. It finished December with $2.5 billion of net cash.
Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)
Fisher & Paykel Healthcare is a designer, manufacturer and seller of products and systems for use in "acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea."
The announcement today related to FY23 revenue guidance. The Fisher & Paykel Healthcare share price is trading 6.5% higher at the time of writing.
At current exchange rates, the ASX 200 healthcare share expects full-year operating revenue to be between $1.55 billion and $1.6 billion.
Management said it was seeing increased sales of its hospital hardware and consumables in China as the country manages its current wave of COVID.
The CEO also explained that the flu season starting early and the "prevalence of respiratory syncytial virus (RSV) also fuelled demand" for hospital consumables in North America in the final months of 2022. However, this "appears to be easing".
On a global basis, the company said that hospital hardware revenue "continues to exceed pre-pandemic levels" and sales of OSA masks "have remained strong".
